a pT and overall survival in clear cell RCC (ccRCC), b Fuhrmann grading and overall survival in ccRCC, c EZH2 immunostaining and overall survival in ccRCC, d EZH2 and recurrence free survival in ccRCC, e CD8 and overall survival in ccRCC, and f CD8 and recurrence free survival in ccRCC. This evidence concerns the gene EZH2 and nonpapillary renal cell carcinoma.